Administration of anti-vascular endothelial growth factor antibody following hepatectomy does not inhibit remnant liver regeneration or growth of remnant metastases

Kasuya,Kazuhiko; Suzuki,Minako; Nagakawa,Yuichi; Suzuki,Yoshiaki; Kikuchi,Satoru; Kyo,Bunso; Matsudo,Takaaki; Itoi,Takao; Tsuchida,Akihiko; Aoki,Tatsuya

doi:10.3892/etm.2011.409

February 2012 Volume 3 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February 2012 Volume 3 Issue 2

Full Size Image

Article Open Access

Administration of anti-vascular endothelial growth factor antibody following hepatectomy does not inhibit remnant liver regeneration or growth of remnant metastases

Authors:
- Kazuhiko Kasuya
- Minako Suzuki
- Yuichi Nagakawa
- Yoshiaki Suzuki
- Satoru Kikuchi
- Bunso Kyo
- Takaaki Matsudo
- Takao Itoi
- Akihiko Tsuchida
- Tatsuya Aoki
View Affiliations / Copyright

Affiliations: Department of Digestive Surgery, Tokyo Medical University, Tokyo, Japan, Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan
Pages: 347-350
|
Published online on: December 6, 2011

https://doi.org/10.3892/etm.2011.409
Expand metrics +

Abstract

In addition to the use of chemotherapeutic agents for the prevention of multiple liver metastases from colorectal cancer, the anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab, is often used, and its effectiveness has been established. By contrast, it has been reported that the use of bevacizumab prior to or following surgery delays wound healing or liver regeneration. In this study, we investigated whether the administration of bevacizumab following hepatectomy inhibits remnant liver regeneration or the growth of remnant metastases. Mice were partially hepatectomized (31% of the liver was removed), transplanted with the murine colorectal cancer cell line, CT26, in the remnant lobe, and intraperitoneally injected with bevacizumab (4 mg/kg) for a total of 6 times. Serum VEGF levels were measured on day 1 following surgery, and each lobe of the liver was weighed on day 14. Serum VEGF levels in non-hepatectomized, tumor-bearing mice exceeded those in their non-tumor-bearing counterparts; however, the administration of bevacizumab did not reduce the serum VEGF levels. The volume of the liver lobe of the hepatectomized, CT26‑transplanted and non-CT26-transplanted mice was 1,349.6 and 735.5 mg, respectively, indicating rapid growth of the CT26 transplant (p=0.023). The volume of the CT26-transplanted lobe of the bevacizumab-administered mice was 1,379.0 mg, which was not significantly different from that (1,349.6 mg) of the non-bevacizumab-administered mice. The volume of the remnant lobe of the bevacizumab-administered mice was 1,051.0 mg, which did not significantly differ from that (957.3 mg) of the non-bevacizumab-administered mice. The administration of bevacizumab following hepatectomy did not delay remnant liver regeneration, and did not suppress the growth of metastases in the remnant lobes or remnant liver regeneration.

View Figures

View References

1.	R AdamV DelvartG PascalRescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survivalAnn Surg240644657200415383792
2.	R AdamR MillerM PitomboDA WichertsRJ De HaasG BitsakouT AloiaTwo-stage hepatectomy approach for initially unresectable colorectal hepatic metastasesSurg Oncol Clin N Am16525536200710.1016/j.soc.2007.04.01617606192
3.	T FukuuraC MikiT InoueK MatsumotoH SuzukiSerum hepatocyte growth factor as an index of disease status of patients with colorectal carcinomaBr J Cancer78454459199810.1038/bjc.1998.5149716026
4.	SS YoonSH KimM GonenProfile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastasesAnn Surg Oncol13353362200610.1245/ASO.2006.03.06016474912
5.	G MenthaS TerrazP MorelDangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver metastasesBr J Surg9695103200910.1002/bjs.643619109800
6.	J FolkmanY ShingAngiogenesisJ Biol Chem26710931109341992
7.	AK GreeneM PuderPartial hepatectomy in the mouse: technique and perioperative managementJ Invest Surg1699102200310.1080/0894193039019442412746193
8.	K MeredithD HaemmerichC QiD MahviHepatic resection but not radiofrequency ablation results in tumor growth and increased growth factor expressionAnn Surg245771776200710.1097/01.sla.0000261319.51744.5917457170
9.	E TaniguchiS SakisakaK MatsuoK TanikawaM SataExpression and role of vascular endothelial growth factor in liver regeneration after partial hepatectomy in ratsJ Histochem Cytochem49121130200110.1177/00221554010490011211118484
10.	C YamamotoS YagiT HoriT IidaK TaniguchiS IsajiS UemotoSignificance of portal venous VEGF during liver regeneration after hepatectomyJ Surg Res1593743201010.1016/j.jss.2008.11.00719394640
11.	SR AlbertsWL HorvathWC SternfeldOxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II studyJ Clin Oncol2392439249200510.1200/JCO.2005.07.74016230673
12.	S BenoistA BrouquetC PennaComplete response of colorectal liver metastases after chemotherapy: does it mean cure?J Clin Oncol2439393945200610.1200/JCO.2006.05.872716921046
13.	M BockhornM GoralskiD ProkofievVEGF is important for early liver regeneration after partial hepatectomyJ Surg Res138291299200710.1016/j.jss.2006.07.02717275844
14.	M BockhornS SchöllmannB OpitzVascular endothelial growth factor does not improve liver regeneration and survival after 90% subtotal liver resectionHepatol Res373533592007

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Administration of anti-vascular endothelial growth factor antibody following hepatectomy does not inhibit remnant liver regeneration or growth of remnant metastases

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles